Bernd Jilma

Has grant

Full Professor

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria Professors in Immunology Immunology professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Bernd Jilma is a Full Professor at the Medical University of Vienna, Austria. His research focuses on immunology, hemostasis, and the impact of nutrition on neurodevelopmental outcomes, as evidenced by his recent publications on COVID-19 mRNA vaccination, factor XI/XIa inhibition, and early solid food intake in preterm infants. His work also explores the pharmacokinetics of therapeutic agents and the role of Toll-like receptors in viral infections.

Recent Grants

Grant: Close

Cellular mediators linking inflammation to thrombosis

Open Date: 2015-03-01

Close Date:

Articles (18)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (18)

Nadja Haiden

AUSTRIA

Bernd Jilma

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (18)

COVID-19 mRNA-1273 vaccination induced mast cell activation with strongly elevated Th2 cytokines in a systemic mastocytosis patient

Preterm Infants on Early Solid Foods and Neurodevelopmental Outcome—A Secondary Outcome Analysis of a Randomized Controlled Trial

Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans

Add-on erythropoietin in autoimmune hemolytic anemia

The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo

Torque Teno Virus Control by the Classical Pathway of Complement Activation—A Retrospective Analysis From a First‐in‐Human Trial Utilizing Sutimlimab

Pharmacokinetics and pharmacodynamics of low doses of recombinant tissue plasminogen activator to establish a model for biosimilarity comparisons

Toll-like Receptors as Pro-Thrombotic Drivers in Viral Infections: A Narrative Review

Endovascular thrombectomy with or without intravenous thrombolysis in large-vessel ischemic stroke: A non-inferiority meta-analysis of 6 randomised controlled trials

Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease

Polyunsaturated Fatty Acid Intake during Complementary Feeding and Neurodevelopmental Outcome in Very Low Birth Weight Infants

Monoclonal antibodies for treatment of cold agglutinin disease

Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study

Recombinant human diamine oxidase prevents hemodynamic effects of continuous histamine infusion in guinea pigs

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial

Clinical pharmacology of antiplatelet drugs

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Collaborators (18)

Nadja Haiden

Gregor Bond

Angelika Berger

Alexander Röth

Marek Postula

Alfonso Iorio

Jolanta Maria Siller-Matula

Aleksandra Gąsecka

Anselm Jorda

Felix Bergmann

Arthur Hosmann

Christoph Neumayer

Christian Schoergenhofer

Anna Nowak-Szwed

Ulrich Jaeger

Thomas Gremmel

Miriam Magdalena Moser

Patricia P. Wadowski

Make your next move.